These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2107736)

  • 1. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.
    Martens LL; Rutten FF; Erkelens DW; Ascoop CA
    Am J Cardiol; 1990 Mar; 65(12):27F-32F. PubMed ID: 2107736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine.
    Martens LL; Rutten FF; Erkelens DW; Ascoop CA
    Am J Med; 1989 Oct; 87(4A):54S-58S. PubMed ID: 2508473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
    Martens LL; Rutten FF; Kuijpens JL; Winter J
    Ned Tijdschr Geneeskd; 1991 Apr; 135(15):655-9. PubMed ID: 1903849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
    Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
    J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.
    Hjalte K; Lindgren B; Persson U
    Pharmacoeconomics; 1992 Mar; 1(3):213-6. PubMed ID: 10147032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with simvastatin compared with cholestyramine.
    Erkelens DW; Baggen MG; Van Doormaal JJ; Kettner M; Koningsberger JC; Mol MJ
    Drugs; 1988; 36 Suppl 3():87-92. PubMed ID: 3254824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
    Rabelink AJ; Hené RJ; Erkelens DW; Joles JA; Koomans HA
    Lancet; 1988 Dec; 2(8624):1335-8. PubMed ID: 2904053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia.
    O'Brien RC; Simons LA; Clifton P; Cooper ME; Jennings GL; Jerums G; Nestel PJ; Sullivan D
    Med J Aust; 1990 May; 152(9):480-3. PubMed ID: 2199801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
    Emmerich J; Aubert I; Bauduceau B; Dachet C; Chanu B; Erlich D; Gautier D; Jacotot B; Rouffy J
    Eur Heart J; 1990 Feb; 11(2):149-55. PubMed ID: 2178931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
    Smit JW; Van Erpecum KJ; Portincasa P; Renooij W; Erkelens DW; Van Berge-Henegouwen GP
    Gut; 1995 Nov; 37(5):654-9. PubMed ID: 8549941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine.
    Oster G; Epstein AM
    JAMA; 1987 Nov; 258(17):2381-7. PubMed ID: 3118060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.
    Thompson D; Oster G
    Pharmacoeconomics; 1992 Jul; 2(1):34-42. PubMed ID: 10146977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
    Geisel J; Oette K; Burrichter H
    Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S).
    Jönsson B; Johannesson M; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    Eur Heart J; 1996 Jul; 17(7):1001-7. PubMed ID: 8809516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.
    Hay JW; Wittels EH; Gotto AM
    Am J Cardiol; 1991 Apr; 67(9):789-96. PubMed ID: 1901436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of simvastatin, a new cholesterol-lowering drug].
    Mol MJ; Stuyt PM; Stalenhoef AF
    Ned Tijdschr Geneeskd; 1989 Feb; 133(7):362-6. PubMed ID: 2927555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.